DK1613355T3 - Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler - Google Patents

Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler

Info

Publication number
DK1613355T3
DK1613355T3 DK04727588.8T DK04727588T DK1613355T3 DK 1613355 T3 DK1613355 T3 DK 1613355T3 DK 04727588 T DK04727588 T DK 04727588T DK 1613355 T3 DK1613355 T3 DK 1613355T3
Authority
DK
Denmark
Prior art keywords
bha
macromolecules
conjugated
propyl gallate
improved absorption
Prior art date
Application number
DK04727588.8T
Other languages
English (en)
Inventor
Roger R C New
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Application granted granted Critical
Publication of DK1613355T3 publication Critical patent/DK1613355T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04727588.8T 2003-04-15 2004-04-15 Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler DK1613355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308734.3A GB0308734D0 (en) 2003-04-15 2003-04-15 Uptake of macromolecules
PCT/GB2004/001651 WO2004091667A1 (en) 2003-04-15 2004-04-15 Uptake of macromolecules

Publications (1)

Publication Number Publication Date
DK1613355T3 true DK1613355T3 (da) 2013-01-02

Family

ID=9956848

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04727588.8T DK1613355T3 (da) 2003-04-15 2004-04-15 Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler

Country Status (19)

Country Link
US (1) US8314058B2 (da)
EP (1) EP1613355B1 (da)
JP (1) JP5047611B2 (da)
KR (1) KR101135784B1 (da)
CN (1) CN100506280C (da)
AU (1) AU2004229217B2 (da)
BR (1) BRPI0409413B8 (da)
CA (1) CA2522146C (da)
CY (1) CY1113461T1 (da)
DK (1) DK1613355T3 (da)
ES (1) ES2394640T3 (da)
GB (1) GB0308734D0 (da)
NZ (1) NZ543172A (da)
PL (1) PL1613355T3 (da)
PT (1) PT1613355E (da)
RU (1) RU2349344C2 (da)
SI (1) SI1613355T1 (da)
WO (1) WO2004091667A1 (da)
ZA (1) ZA200508344B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0603252D0 (en) 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
WO2008132731A2 (en) * 2007-04-26 2008-11-06 Oramed Pharmaceuticals, Inc Methods and compositions for rectal administration of insulin
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
KR102236462B1 (ko) 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
KR101748053B1 (ko) 2012-10-17 2017-06-15 메틸레이션 사이언시즈 인터내셔널 에스알엘 S-아데노실메티오닌 및 갈산 에스테르가 포함된 조성물
MA50047A (fr) 2017-10-31 2020-07-08 Medimmune Ltd Administration orale d'analogues peptidiques de glp-1
US20230109708A1 (en) * 2020-01-23 2023-04-13 Axcess (UK) Ltd Cellular Uptake
CN116940384A (zh) * 2020-11-27 2023-10-24 D&D制药技术股份有限公司 具有与生物素部分、脂肪酸部分或其组合偶联的生物活性材料缀合物的口服制剂
WO2022157676A1 (en) * 2021-01-22 2022-07-28 Axcess (UK) Ltd Edta and egta for use in preserving the integrity of therapeutic compounds
GB2625490A (en) * 2021-01-27 2024-06-19 D&D Pharmatech Inc Pharmaceutical composition comprising large physiologically active substance and excipient
EP4400094A4 (en) * 2021-09-07 2025-08-27 D&D Pharmatech Inc PHARMACEUTICAL COMPOSITION COMPRISING A PHYSIOLOGICALLY ACTIVE SUBSTANCE AND AN EXCIPIENT
KR102412437B1 (ko) 2022-03-10 2022-06-23 주식회사 보은기계 선택적 시공이 가능한 수로시스템
EP4712796A2 (en) 2023-05-15 2026-03-25 Bonafide Health, LLC Sleep-improving compositions and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB354184A (en) 1929-04-30 1931-07-29 Pharmagans Pharmaceutisches In An improved process for the production of hormone preparations
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
JPS5257313A (en) 1975-11-07 1977-05-11 Yamanouchi Pharmaceut Co Ltd Manufacture of micellar insuline emulsion preparations
JPS56138168A (en) * 1980-03-31 1981-10-28 Teijin Ltd Movel active vitamin d3 derivative composition
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4789660A (en) 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IT1251685B (it) 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
JPH05246846A (ja) 1992-03-03 1993-09-24 Taiyo Kagaku Co Ltd 蛋白質の消化促進組成物
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU1808897A (en) * 1995-12-13 1997-07-03 Dullatur Limited A calcitonin preparation
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
CA2265767C (en) * 1997-07-11 2007-12-04 Nobuyuki Hanamura Stable pharmaceutical composition including 4,5-epoxy-morphinan derivative
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
WO2000022909A2 (en) * 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE60001667T2 (de) 2000-03-31 2004-01-29 Council Scient Ind Res Getreidenahrungsmittel mit hohem nährwert
EP1292324A2 (en) 2000-05-05 2003-03-19 Novo Nordisk A/S Critical illness neuropathy
ES2292496T3 (es) 2000-09-18 2008-03-16 Rpg Life Sciences Limited Formulacion autoemulsionable con elevada actividad inmunosupresora y bioabsorbente.
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20030232078A1 (en) 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules

Also Published As

Publication number Publication date
CN1805759A (zh) 2006-07-19
SI1613355T1 (sl) 2013-01-31
NZ543172A (en) 2009-05-31
ES2394640T3 (es) 2013-02-04
JP5047611B2 (ja) 2012-10-10
KR101135784B1 (ko) 2012-04-16
US8314058B2 (en) 2012-11-20
CA2522146C (en) 2012-06-12
EP1613355A1 (en) 2006-01-11
JP2006523663A (ja) 2006-10-19
CY1113461T1 (el) 2016-06-22
BRPI0409413B8 (pt) 2021-05-25
BRPI0409413B1 (pt) 2017-05-02
PL1613355T3 (pl) 2013-09-30
BRPI0409413A (pt) 2006-04-25
RU2349344C2 (ru) 2009-03-20
KR20060021293A (ko) 2006-03-07
EP1613355B1 (en) 2012-09-19
PT1613355E (pt) 2012-12-26
CA2522146A1 (en) 2005-10-13
AU2004229217A1 (en) 2004-10-28
HK1078277A1 (en) 2006-03-10
RU2005135428A (ru) 2006-06-10
CN100506280C (zh) 2009-07-01
GB0308734D0 (en) 2003-05-21
ZA200508344B (en) 2007-12-27
US20060122097A1 (en) 2006-06-08
AU2004229217B2 (en) 2010-03-25
WO2004091667A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1651839T3 (da) Afstands- og sprossestykker til isolering af glasenheder
IS7701A (is) Arípíprazól samsett lyfjaform og aðferð
DK1715893T3 (da) Direkte kompressionsformulering og fremgangsmåde
DK1968429T3 (da) Fremgangsmåde og system til stabilisering af sensorer
DE502005009089D1 (de) 1-methyl-3-trifluormethyl-pyrazol-4-carbonsäure-(ortho-phenyl)-anilide und ihre verwendung als fungizid
DK1761266T3 (da) Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
DE602004004267D1 (de) Formtrennmittelzusammensetzung und verfahren damit
ATE442348T1 (de) Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
DE602004026628D1 (de) Mikroporöse verbundfolie, herstellungsverfahren dafür und verwendung
EP1701731A4 (en) GLP-1 (9-36) METHOD AND COMPOSITIONS
DK1974017T4 (da) Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
DK1948695T3 (da) Immunogene sammensætninger og fremgangsmåder til andvendelse
DK1874557T3 (da) Identitetsdokument og fremgangsmåde til fremstilling deraf
NO20052266D0 (no) Dunleks rustfritt stal og fremstillingsmetode derav
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
SI1613355T1 (sl) Nekonjugirana žolčna kislina skupaj s propil galatom in/ali BHA za povečanje absorpcije makromolekul
DK1765376T3 (da) Topiske sammensætninger og anvendelse deraf til behandling af epitel-relaterede tilstande
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
DK1754960T3 (da) Forglasningselement og fremgangsmåde til fremstilling heraf
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
EP1847630A4 (en) HIGHLY CARBURATED / VOLTAGE-FREE REMOVED COMPONENT AND METHOD OF MANUFACTURING THEREOF
DK1882054T3 (da) Korrosionsbeskyttelsesanordning og fremgangsmåde
DE602006019849D1 (de) Proteinspaltungsverfahren und verwendung davon